^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GT 316

i
Other names: GT 316, GT316
Associations
Trials
Company:
Grit Biotechnology
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
1year
New P1 trial • Metastases
|
GT 316
over1year
The discovery and development of a CRISPR/Cas9-engineered tumor-infiltrating lymphocytes product (GT316) as a next-generation TIL therapy (AACR 2023)
In summary, these data demonstrated that our ImmuT Finder® platform enables unbiased discovery of potent and novel targets for the development of T cell therapy and support the clinical assessment of GT316 as a next-generation TIL therapy. Currently, an investigator-initiated trial of GT316 is ongoing in China.
Tumor-infiltrating lymphocyte
|
IL2 (Interleukin 2)
|
GT 316